Premium
The state of dietary supplement adverse event reporting in the United States
Author(s) -
Gardiner Paula,
Sarma Dandapantula N.,
Dog Tieraona Low,
Barrett Marilyn L.,
Chavez Mary L.,
Ko Richard,
Mahady Gail B.,
Marles Robin J.,
Pellicore Linda S.,
Giancaspro Gabriel I.
Publication year - 2008
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1627
Subject(s) - formulary , medicine , environmental health , food and drug administration , public health , adverse effect , medical emergency , family medicine , pharmacology , nursing
Purpose The Dietary Supplements Information Expert Committee (DSI‐EC; the Committee) of the United States Pharmacopeial Convention (USP) reviews safety profiles of dietary supplements before development of USP–National Formulary ( USP–NF ) quality monographs. Because the veracity of dietary supplement adverse event reports (DS AERs) directly affects DSI‐EC safety reviews, the Committee reviewed the current status of DS AER reporting in the US. Methods DSI‐EC reviewed PubMed searches, information from the US Food and Drug Administration's (FDA) MedWatch program, the Toxic Exposure Surveillance System (TESS) of the American Association of Poison Control Centers (AAPCC), and reports from US and other agencies. DSI‐EC analyzed this information to identify key factors that affect the quality of DS AERs. Results The overall incidence of DS AERs appears generally to be low. However, the primary reporting portal (FDA MedWatch) receives fewer AERs than do poison control centers (PCCs), and limited coordination exists among national and international surveillance programs for evaluating signals that may indicate potential public health risks. Both inadequate and poor‐quality reporting of DS AERs are major limitations of DS safety monitoring in the US. Conclusions Based on its assessments, the Committee advances recommendations to improve the quality of reporting, monitoring, and assessing DS AERs. These include (1) enhanced data collection approaches, (2) improved coordination of AER surveillance programs, (3) strengthening of educational programs for public and health care sectors, and (4) conduct of research concerning the safety of DS. If taken, these approaches are expected to improve the health and well‐being of DS users. Copyright © 2008 John Wiley & Sons, Ltd.